Novartis AG replaced the top managers at its Japanese unit on Thursday after a third-party probe found employees had acted questionably in clinical trials on a leukaemia treatment. The probe's findings included possible destruction of evidence and the potential obtaining of patients' personal data by employees of the Japanese unit, Novartis Pharma K.K. said in a statement. Novartis said there was a possibility the investigation, which was commissioned by the company and is scheduled to be complete by summer, could uncover problems with other doctor-led clinical research. David Epstein, head of Novartis Pharmaceuticals, said the actions of the employees violated the company's ethical standards and acknowledged a need to rebuild the Japanese unit under the new management team.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment